pineapples.jpgbutterflies1.jpgbutterfly4.jpgdice dealer 1.jpggem pile.jpgSeC in your future.jpgxmas bong.jpgbutterfly2.jpgdice pile.jpgnewpackaging.jpgBCP.jpggemmies with nug.jpgwhite russian.jpgbutterfly of death.jpgpina colada.jpgtaquila sunrise.jpgpineapple_1.jpg
2 dice.jpgbutterflies2.jpgbutterfly3.jpgpineapple.jpgwhiskey sour.jpgbutterfly1.jpgcherries.jpggem.jpglemon.jpggrapes.jpgold fashioned.jpgbanana.jpgmimosa.jpgfruitsgroup.jpgmojito.jpgdice dealer 2.jpg

Please do not under any circumstances replace prescribed medication(s) with cannabis and/or cannabis infused products without consulting a licensed physician first.

Safe Consumption

We want you to have the best experience possible with our products, and a big part of that is making sure you are aware and comfortable with your limitations.
As with any other drug, there can be some nasty side effects that come with the over-consumption of edibles, so it is important to understand your tolerance level before eating any type of THC infused treat.


Here is a guide to assist in finding a THC mg level that works best for you:


safety flow chart

Cannabis Consumption FAQ

All underlined terms can be found in the Glossary section.

The use of cannabis, oral cannabis extracts (OCEs), and synthetic cannabinoids (man-made drugs designed to be structurally similar to naturally occurring cannabinoids), has been studied for many medical conditions, with varying results.

A recent meta-analysis [1] published by the National Academy of Sciences, Engineering, and Medicine reviewed over 10,700 publications related to the use of cannabis in a medical context. This large-scale review produced the following conclusions:

The medical conditions for which conclusive evidence [1] exists to support the use of these substances:

  • Chronic pain in adults
  • Chemotherapy-induced nausea and vomiting
  • Symptoms of spasticity in multiple sclerosis (MS) (patient reported)
The medical conditions for which moderate evidence [1] exists to support the use of these substances:
  • Short-term sleep disturbance in obstructive sleep apnea (OSA)
  • Fibromyalgia
  • Multiple sclerosis
The medical conditions for which limited evidence [1] exists to support the use of these substances:
  • Increasing appetite, decreasing weight loss associated with HIV/AIDS
  • Symptoms of spasticity in MS (clinician-measured)
  • Symptoms of Tourette syndrome
  • Anxiety in individuals with social anxiety disorders (measured by public speaking test)
  • Symptoms of post-traumatic stress disorder (PTSD)
  • Improved outcomes in terms of mortality and disability following traumatic brain injury or intracranial hemmorhage
If you are interested in trying cannabis products for your medical condition, and it is not listed above, it means that minimal or no credible evidence currently exists in published scientific literature to support the usage of cannabinoids for that condition. It must also be acknowledged that the above evidence is for treatment of symptoms. Cannabinoids should not be thought of as “cures” for any of these conditions.
Lastly, it is always important to be informed of the risks of cannabis or cannabinoid use, as an evidence-based treatment for symptoms, or otherwise.

Using cannabis in any form comes along with inherent risk. The same thing may be said about consuming prescribed pharmaceuticals, alcohol, tobacco products, fast food, driving a car, owning firearms, and so on. Educating yourself on these risks is essential so that an informed decision can be made.

Adverse short-term side effects:

Everyone reacts differently to cannabis, and different people may be more or less sensitive than others to the effects of cannabis. The cannabis high is a pleasant experience for many. However, negative experiences are possible due to inexperience, over-consumption, use in an unfamiliar setting or negative state of mind, and differences in how the cannabis high is experienced by each user.

Listed below are some possible negative effects of cannabis:

  • Feelings of strong anxiety, panic, or paranoia
  • Hallucinations
  • Disorientation, and altered perception of time
  • Increased heart rate, and feeling your heart pounding in your chest (palpitations)
  • Fluctuations in blood pressure, potentially causing light-headedness
  • Impaired short-term memory, and ability for form thoughts or articulate ideas verbally
  • Impaired motor coordination
    • Under NO circumstances should you operate a motor vehicle, or heavy machinery while under the influence of cannabis
  • Psychotic symptoms, and depersonalization are rare, but possible
Cannabis use disorder (CUD):

Although cannabis does not produce strong features of physical addiction/dependence in the same way that long-term heavy use of alcohol or benzodiazepines (such as Valium aka diazepam) does, it is still considered to produce a psychological dependency disorder.
Cannabis dependency, officially known as CUD, may be characterized as continued use of cannabis despite clinically significant impairment in domains such as work, educational, relationship, and financial responsibilities [2]. A 2015 survey found that of the 22.2 million Americans who report currently using cannabis, 4.2 million reported experiencing symptoms consistent with CUD in the past year [3]. However, CUD can be successfully treated with psychosocial therapies, and personal motivation to quit or reduce use [4,5]. If you feel that your cannabis use has become a problem, talk to your doctor, or contact a local drug rehabilitation center about getting help!

Involvement in psychiatric/psychological problems:

Psychoactive substances often carry with them risks related to mental health issues, as well as addiction and dependence (outlined above), and cannabis is no exception.
Of particular note is the substantial evidence to suggest that there is a statistical association between the use of cannabis and the development of schizophrenia, and other psychotic disorders [1,6,7]. This risk appears to increase with increased frequency of use. Although as of yet no direct mechanism for how cannabis could directly cause psychotic disorders has been identified, this correlation is well established and warrants caution, especially among users with a family history of psychotic disorders.

There is moderate evidence [1] supporting a statistical association between cannabis use and:
  • Worsened symptoms of bipolar disorder with regular use
  • Increased chance of developing depressive disorders
  • Increased risk of suicidal ideation, attempts, and completion
  • Social anxiety disorder
There is limited evidence [1] of a statistical association between cannabis use and:
  • Increased risk of developing bipolar disorder with regular use
  • Increased risk of anxiety disorders, and symptoms of anxiety
  • Worsened symptoms of PTSD
  • Impaired academic achievement
  • Long term impairment in learning, memory, and attention following chronic use
If you begin to experience any kind of psychological distress, during cannabis use, between instances of cannabis use, or unrelated to cannabis use, it is imperative that you talk to your doctor, or access local mental health resources. Help is available to you, and you are not alone!

Use during pregnancy:

THC in the bloodstream of a pregnant woman will cross the placenta, resulting in exposure of the developing fetus to TCH [8]. Cannabis use during pregnancy has been associated with negative outcomes for the infant. Substantial evidence exists to support an association between use during pregnancy and lower birth weight of the infant [1,9]. There is also limited evidence supporting an association with pregnancy complications for the mother, as well as increased risk that the infant will require intensive care following birth [1,9,10].
To mitigate these risks, if you are pregnant, think you may be pregnant, or are trying to conceive, you should abstain from cannabis use completely.

Effects on lungs and respiratory tract:

Just like inhaling any other kind of smoke, inhaling cannabis smoke stresses the respiratory tract and lungs. In fact, relative to tobacco cigarettes, smoking marijuana cigarettes was found to produce almost 5 times as much carbon monoxide, and 3 times as much inhaled tar [11]. Current research on cannabis smoking and respiratory diseases is complicated by a history of tobacco smoking that is common among the studied populations. However, when tobacco smoking was controlled for, long-term cannabis smoking was associated with worsened respiratory symptoms of cough, phlegm production, and wheezing [12]. Although no strong association has yet been found between cannabis smoking and lung cancer [1,13], caution is still warranted due to the plausibility of such an association.
Use of a vaporizer, or consuming cannabis in edible formats negates these risks.

*DISCLAIMER: The following calculations are meant to illustrate a point, and should under NO CIRCUMSTANCES be used as a guidline, or licence for consumption of extreme amounts of cannabis*

There have been no reported cases of a lethal overdose due to consuming cannabis by itself. LD50 is a common method of reporting toxicity, and the LD50 of THC is extremely high. In a study on rats, the LD50 for an oral preparation of THC was found to be between 800-1270 mg/kg body mass [14]. The LD50 for inhaled marijuana smoke was 36-40 mg/kg. This suggests that a 160 lb human (about 73 kg) with no tolerance would have to eat approximately 58400-92710 mg of THC, or smoke between 22-24 g of dried marijuana (assuming 12% THC marijuana) all at once to have a 50% chance of a lethal overdose.

Having a lethal overdose from cannabis alone is not impossible. However, given the extremely high doses that would be required, accidentally having a lethal overdose is incredibly unlikely.

When cannabis smoke or vapour is inhaled, cannabinoids enter your bloodstream through your lungs, resulting in a rapid onset of the short-term effects that characterize the cannabis “high”. Blood THC concentrations peak within minutes of smoking, and decrease significantly over the course of the following hour [15]. Consuming cannabis this way can allow for the high to be controlled more easily by the user, due to the rapid onset, and relatively rapid waning of the effects relative to oral consumption.

When cannabis edibles are eaten, cannabinoids enter your bloodstream by being absorbed through the lining of your gastrointestinal tract. This process occurs significantly slower than it does with inhaling cannabis smoke or vapor, resulting in a more gradual onset of the high over the course of 1-6 hours [16,17], as well as a longer lasting high. Consuming cannabis via edibles completely avoids the risks of inhaling smoke. However, due to the gradual onset of effects, and the conversion of a portion of the ingested THC to the active metabolite 11-OH-THC by the liver [17], it is easier to overshoot the desired dosage (for example, by consumers mistakenly believing that they have not eaten enough to feel the effects, when in reality the onset of the effects has not occurred yet) resulting in a potentially uncomfortable and unpleasant experience.

The Products by SeC Safe Consumption flow chart is a useful tool to help avoid overconsumption, and ensure a safe and enjoyable experience!

Cannabis can be readily detected in laboratory tests. If you used cannabis today, you could test positive for cannabis for 1-3 days following this consumption [18]. However, long-term use may still produce positive results even after months of cannabis abstinence due to the high sensitivity of lab tests, which can detect THC breakdown products on the order of nanograms (1 ng = 0.000000001 g) [19].

This relatively long window in which cannabis use can be detected is due to the chemical properties of cannabinoids, and the chemical by-products created by your body as it breaks these molecules down. The majority of cannabinoids are fat soluble, meaning that they will dissolve easily in fats, but not in water. As a result, cannabinoids and their fat-soluble breakdown products tend to linger in the fat stores of your body, and are slowly excreted over time.

Cannabinoid breakdown products are excreted from your body primarily in feces, and urine [17,20]. Urine tests are a common method of detecting cannabis use. Other methods for detecting recent cannabis consumption include hair testing (for breakdown products that become embedded in hair as it grows), saliva tests, and blood tests.

Ultimately, if you are aware that you may be tested for cannabis use, and that a positive test will have a negative impact on your career, relationships, or any other aspect of your life, you should consider abstaining from cannabis use in any form.

Cannabinoids

  • A family of molecules that are similar to each other in chemical structure and properties, and bind to a specific set of chemical receptors on the surfaces of various cells in your body. This binding process and its effects on the cells is how the active ingredients in the cannabis plant exert their effects. These molecules may be produced naturally in plants (phytocannabinoids ex. THC) and animals (endocannabinoids ex. anandamide), or artificially created (synthetic cannabinoids).
Meta-analysis
  • A type of research study whose objective is to investigate, and compare the results of numerous scientific studies. These are done in order to draw stronger conclusions more confidently about a given area of research, or research question, than could be possibly drawn from any of these studies individually.
“Conclusive evidence” As defined in [1]
  • “For this level of evidence, there are many supportive findings from good-quality studies with no credible opposing findings. A firm conclusion can be made, and the limitations to the evidence, including chance, bias, and confounding factors, can be ruled out with reasonable confidence.”
“Substantial evidence” As defined in [1]
  • “For this level of evidence, there are several supportive findings from good-quality studies with very few or no credible opposing findings. A firm conclusion can be made, but minor limitations, including chance, bias, and confounding factors, cannot be ruled out with reasonable confidence.”
“Moderate evidence” As defined in [1]
  • “For this level of evidence, there are several supportive findings from good- to fair-quality studies with very few or no credible opposing findings. A general conclusion an be made, but limitations, including chance, bias, and confounding factors, cannot be ruled out with reasonable confidence.”
“Limited evidence” As defined in [1]
  • “For this level of evidence, there are supportive findings from fair-quality studies or mixed findings with most favoring one conclusion. A conclusion can be made, but there is significant uncertainty due to chance, bias, and confounding factors.”
“No or insufficient evidence…” As defined in [1]
  • For this level of evidence, there are mixed findings, a single poor study, or health endpoint has not been studied at all. No conclusion can be made because of substantial uncertainty due to chance, bias, and confounding factors.”
Psychoactive
  • A psychoactive substance is one that affects the activity and function of the brain, thereby producing perceptual changes, altered mood, behaviour, and level of consciousness. To give other common examples, caffeine is the psychoactive component in coffee, and ethanol is the psychoactive component of alcoholic beverages.
Physical addiction
  • A condition caused by long-term use of a drug, wherein discontinuation of use causes unpleasant, physical and psychological symptoms. In severe instances, the physical symptoms may be potentially life threatening (ex delirium tremens aka DTs in alcohol withdrawal). This is due to the adaptation of the nervous system to repeated exposure to the drug over time. When the drug is no longer present, these adaptations are no longer assisting the nervous system in functioning normally, and instead produce symptoms of drug withdrawal.
LD50
  • An abbreviation for “Lethal dose-50%”, also known as the “median lethal dose”. In scientific studies of toxicity, the LD50 is the dose that was lethal in 50% of the animal subjects tested. Higher toxicity is indicated by a lower LD50.
Statistical association
  • A term indicating that a connection exists between two measured variables that is highly unlikely to be due to mere chance. Associations may be due to changes in one variable directly leading to changes in the other, but they may also be due to other factors, such as a third unmeasured variable that is connected to both measured variables, mediating the relationship. As a result, we cannot say with certainty that one thing causes another, even if there is a statistical association between those two things.

  1. National Academies of Sciences, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press. doi: 10.17226/24625. (http://nap.edu/24625)

  2. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders. (5th Edition). Washington, DC.

  3. CBHSQ (Center for Behavioral Health Statistics and Quality). 2015. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50).

  4. Elkashef, A., Voccia, F., Huestis, M., Haney, M., Budney, A., Gruber, B., el-Gueb aly, N. (2008). Marijuana neurobiology and treatment. Subst Abus. 29:17-29.

  5. Budney, A.J., Moore, B.A. (2002). Development and consequences of cannabis dependence. J Clin Pharmacol. 42:28S-33S.

  6. Foti, D.J., Kotov, R., Guey, L.T., Bromet, E.J. (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 167:987-993.

  7. Eden Evins, A., Green, A.I., Kane, J.M., Murray, R.M. (2012). The effect of marijuana use on the risk for schizophrenia. J Clin Psychiatry. 73:1463-1468

  8. Bailey, J.R., Cunny, H.C., Paule, G., Slikker, W., Jr. (1987). Fetal disposition of delta-9-tetrahydrocannabinol (TH) during late pregnancy in the rhesus monkey. Toxicology and Applied Pharmacology. 90:315-321.

  9. Gunn, J.K.L., Rosales, K.E., Center, A., Nunez, S.J., Gibson, C.C., Ehiri, J.E. (2016). Prenatal exposure to cannabis and maternal and child health outcomes: A systematic review and meta-analysis. BMJ Open. 6:e009986.

  10. Warshak, C.R., Regan, J., Moore, B., Magner, K., Kritzer, S., Van Hook, J. (2015). Association between marijuana use and adverse obstetrical and neonatal outcomes. Journal of Perinatology. 35:991-995.

  11. Wu, T.C., Tashkin, D.P., Djahed, B., Rose, J.E. (1988). Pulmonary hazards of smoking marijuana as compared with tobacco. New England Journal of Medicine. 318:347-351.

  12. Tetrault, J.M., Crothers, K., Moore, B.A., Mehra, R., Concato, J., Fiellin, D.A. (2007). Effects of marijuana smoking on pulmonary function and respiratory complications: A systematic review. Archives of Internal Medicine. 167:221-228.

  13. Mehra, R., Moore, B.A., Crothers, K., Tetrault, J., Fiellin, D.A. (2006). The association between marijuana smoking and lung cancer: A systematic review. Archives of Internal Medicine. 166:1359-1367.

  14. Rosenkrantz, H., Heyman, I.A., Braude, M.C. (1974). Inhalation, parenteral and oral LD50 values of delta-9-tetrahydrocannabinol in Fischer rats. Toxicology and Applied Pharmacology. 28:18-27.

  15. Huestis, M.A., Henningfield, J.E., Cone, E.J. (1992). Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and TCHCOOH during and after smoking marijuana. J Anal Toxicol. 16:276-282.

  16. Ohlsson, A., Lindgren, J.E., Wahlen, A., Agurell, S., Hollisted, L.E., Gillespie, H.K. (1980). Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 28:409-416.

  17. Wall, M.E., Sadler, B.M., Brine, D., Taylor, H., Perez-Reyes, M. (1083). Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 34:352-363.

  18. https://www.redwoodtoxicology.com/resources/drug_info/marijuana

  19. Proposed Revisions to Mandatory Guidelines for Federal Workplace Drug Testing Programs. (2004). Fed Reg. 69:19673-19732.

  20. Harvey, D.J. (2001). Absorption, distribution, and biotransformation of the cannabinoids in Marijuana and Medicine (Mahas, G.G., Sutin, K.M., Harvey, D.J., Agurell, S., eds.), Humana Press, Totowa, NJ, pp 91-103.